- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00316784
IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA
March 19, 2009 updated by: IDEA AG
A Double-Blind, Placebo-Controlled Evaluation of Dose Related Safety and Efficacy of Epicutaneously Applied IDEA-033 for 3 Months Treatment of OA of the Knee Followed by a Double-Blind, Dose-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 for 12 Weeks Treatment of OA of the Knee
The study objective is the eluciation of the dose-response function in efficacy (and possibly safety) in order to determine an optimal dose with respect to efficacy and safety.
The study is designed with three dose levels and one placebo control.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
704
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- clinical diagnosis of OA in at least one knee for a minimum of 6 months
- aged 18-75 years old
- eligible subjects must have used an oral or rectal NSAID on at least three days per week during the three months before screening or on at least 25 of the 30 days before screening, but be dissatisfied with the current NSAID treatment
- at baseline visit WOMAC pain subscale at least 40 mm, and at least 15 mm greater than at the screening visit in the index knee
- radiographic evidence consistent with OA criteria of grade 2 or 3 according to Kellgren & Lawrence in the index knee. Radiographs mus have been taken during the 6 months before baseline.
- American College of Rheumatology (ACR) functional class I, II or III
Exclusion Criteria:
- intraarticular injections or arthroscopy of the index knee within 3 months prior to screening, or planned during the study
- history, physical examinations or radiographs suggestive of other rhematic diseases
- known hypersensitivity or contraindication to ketoprofen; NSAID idiosyncrasy
- history of peptic ulcers
- severe liver or gastro-intestinal disease within the last 6 months
- injections or change in oral treatment regimen of glucosamine, chondroitin sulfate, hyaluronic acid, shark cartilage, or vitamin E within 3 months prior to screening
- oral or parenteral corticosteroids within 3 months prior to screening
- analgesic therapy for chronic or recurrent pain conditions for indications other than OA
- immunosuppressants within 3 months prior to screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC Pain subscale (primary)
|
patient global assessment of response to therapy measured on a 5-point Likert Scale at week 12 or end of study measurements (co-primary)
|
change from baseline at week 12 (or end of study measurements) on the Visual Analogue Scale version of the entire WOMAC function subscale (co-primary)
|
Secondary Outcome Measures
Outcome Measure |
---|
Change from baseline at week 12 (or end of study measurements) for Physician's Global Assessment of OA and for observed function (TUG)
|
Mean number of rescue medication taken per day while in the study
|
Number of withdrawals and time to discontinuation of the study due to lack of efficacy
|
Time to onset (in days) of pain relief and time to onset of new flares during treatment
|
Change from baseline on the vitality subscale of the SF-36 health survey and the EURO QoL
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gerold Stucki, Prof, MD, department of physical medicine and rehabilitation of universtity Munich
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2005
Study Completion
May 1, 2006
Study Registration Dates
First Submitted
April 19, 2006
First Submitted That Met QC Criteria
April 19, 2006
First Posted (Estimate)
April 21, 2006
Study Record Updates
Last Update Posted (Estimate)
March 20, 2009
Last Update Submitted That Met QC Criteria
March 19, 2009
Last Verified
March 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-033-III-02/E
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis; Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on IDEA-033 (and rescue medication)
-
IDEA AGCompletedJoint Pain | Musculoskeletal Pain | Stiffness | Soft Tissue Inflammation in Designated Target Area(s)Germany
-
IDEA AGCompletedOsteoarthritis, KneeUnited States
-
Medical University of SilesiaSilesian University of MedicineUnknown
-
Merck Sharp & Dohme LLCTerminated
-
GlaxoSmithKlineTerminatedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
Gachon University Gil Medical CenterKorea Research FoundationCompletedAllergic RhinitisKorea, Republic of
-
GlaxoSmithKlineWithdrawnAsthmaUnited States, Spain
-
Merck Sharp & Dohme LLCCompleted
-
Ain Shams UniversityCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveAustralia, Canada, Germany, Poland, Romania, Spain, United States, Korea, Republic of, Netherlands